# US 2001/0055755 A1 · Dendritic marker-expressing macrophage cultures and methods for reactivating latent HCMV

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0055755 A1
- Document ID: US20010055755A1
- Status: Published application
- Kind: A1
- Application number: 09/810,328
- Filed: 2001-03-15
- Published: 2001-12-27
- Earliest claimed: 1997-10-01
- Inventors: Cecilia Soderberg-Naucler; Kenneth Fish; Ashlee Moses; Daniel Streblow; Jay Nelson
- Web page: https://patentgrep.com/patent/US20010055755A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/23: Interleukins [IL]
- C12N 2501/24: Interferons [IFN]
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2502/11: blood or immune system cells
- C12N 2503/00: Use of cells in diagnostics
- C12N 2710/16651: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods of latent virus reactivation in monocyte-derived macrophages through allogeneic stimulation of peripheral blood mononuclear cells (“PBMC”), methods of culturing virus, and cultures of virally permissive monocyte-derived macrophages.

## Claims

### Claim 1

A method of replicating viruses in virally permissive monocyte-derived macrophages, the method comprising the steps of:
(a) culturing monocytes under conditions where the monocytes are in fluid communication with viable, allogeneically stimulated peripheral blood mononuclear cells (PBMC) to activate the monocytes to differentiate into virally permissive monocyte-derived macrophages; and
(b) permitting viral replication in the monocyte-derived macrophages, where the virus is either latent in the monocytes or exogenously added to the culture.

### Claim 2 (depends on 1)

A method of claim 1, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83 and CD14.

### Claim 3 (depends on 1)

A method of claim 1, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 4 (depends on 1)

A method of claim 1, wherein the allogeneically stimulated cells include CD4+ and CD8+ cells.

### Claim 5 (depends on 1)

A method of claim 1, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 6 (depends on 5)

A method of claim 5, wherein the virus is CMV.

### Claim 7 (depends on 1)

A method of claim 1, wherein the monocyte-derived macrophages are human.

### Claim 8

A method for screening for inhibitors of virus production using virally permissive monocyte-derived macrophages, the method comprising the steps of:
(a) culturing monocytes under conditions where the monocytes are in fluid communication with viable, allogeneically stimulated peripheral blood mononuclear cells (PBMC) to activate the monocytes to differentiate into virally permissive monocyte-derived macrophages;
(b) permitting viral replication in the monocyte-derived macrophages, where the virus is either latent in the monocytes or exogenously added to the culture;
(c) contacting the monocyte-derived macrophages of step (b) with substances suspected of having the ability to inhibit viral production; and
(d) detecting the level of virus production in the monocytes-derived macrophages.

### Claim 9 (depends on 8)

A method of claim 8, wherein the monocyte-derived macrophages have a majority population of cell bearing CD83 and CD14.

### Claim 10 (depends on 8)

A method of claim 8, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 11 (depends on 8)

A method of claim 8, wherein the allogeneically stimulated cells include CD4+ and CD8+ cells.

### Claim 12 (depends on 8)

A method of claim 8, wherein the virus is latent.

### Claim 13 (depends on 8)

A method of claim 8, wherein the monocyte-derived macrophages are human.

### Claim 14 (depends on 8)

A method of claim 8, wherein the substances are inhibitors of viral proteases.

### Claim 15 (depends on 8)

A method of claim 8, wherein the substances are antisense molecules that bind to nucleic acid generated by the virus.

### Claim 16 (depends on 8)

A method of claim 8, wherein the substances are antisense molecules that are complementary to mRNA encoded by a viral genome.

### Claim 17 (depends on 16)

A method of claim 16, wherein the substances are ribozymes complementary to mRNA encoded by a viral genome.

### Claim 18 (depends on 8)

A method of claim 8, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 19 (depends on 18)

A method of claim 18, wherein the virus is CMV.

### Claim 20 (depends on 18)

A method of claim 18, wherein the substances inhibit a viral protein selected from the group consisting of CMV DNA polymerase, UL80, and UL89.

### Claim 21

A stable culture of virally permissive monocyte-derived macrophages, wherein the monocyte-derived macrophages are derived from monocytes exposed to allogeneically stimulated peripheral blood mononuclear cells (PBMC) for a time sufficient to and a concentration sufficient to: (i) stimulate active differentiation of the monocytes into monocyte-derived macrophages, and (ii) stimulate viral production in the monocyte-derived macrophages; and, wherein the virally permissive monocyte-derived macrophages produce at least 10,000 fold greater virus than non-allogeneically stimulated monocytes.

### Claim 22 (depends on 21)

A culture of claim 21, wherein the majority of the monocyte-derived macrophages bear CD83 and CD14.

### Claim 23 (depends on 21)

A culture of claim 21, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 24 (depends on 21)

A culture of claim 21, wherein the monocyte-derived macrophages produce a virus selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 25 (depends on 24)

A culture of claim 24, wherein the virus is CMV.

### Claim 26

A stable culture of virally permissive monocyte-derived macrophages having a population defined as at least 85% bearing CD83 and CD14.

### Claim 27 (depends on 26)

A culture of claim 26, wherein the monocyte derived-macrophages have a population of at least 85% of the cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 28 (depends on 26)

A culture of claim 26, wherein the virus is latent.

### Claim 29 (depends on 26)

A culture of claim 26, wherein the monocyte-derived macrophages produce a virus selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 30 (depends on 29)

A culture of claim 29, wherein the virus is CMV.

### Claim 31 (depends on 26)

A culture of claim 26, wherein the monocyte-derived macrophages are human.

### Claim 32

A method of culturing virally permissive monocyte-derived macrophages, the method comprising the step of culturing monocytes under conditions where the monocytes are in fluid communication with viable, allogeneically stimulated peripheral blood mononuclear cells (PBMC) to activate the monocytes to differentiate into monocyte-derived macrophages.

### Claim 33 (depends on 32)

A method of claim 32, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83 and CD14.

### Claim 34 (depends on 32)

A method of claim 32, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 35 (depends on 32)

A method of claim 32, wherein the allogeneically stimulated cells include CD4+ and CD8+ cells.

### Claim 36 (depends on 32)

A method of claim 32, wherein the monocyte-derived macrophages are human.

### Claim 37

A stable culture of virally permissive monocyte-derived macrophages having the following characteristics:
(i) comprising dendritic cell markers CD68, CD83, and CD1a;
(ii) comprising macrophage cell markers CD64 and CD14; and
(iii) derived from CD14+ monocytes.

### Claim 38

A method of replicating viruses in virally permissive monocyte-derived macrophages, the method comprising the steps of:
(a) culturing CD14+ monocytes under conditions where the monocytes are exposed to conditioned media comprising IFNγ in an amount sufficient to activate the monocytes to differentiate into virally permissive monocyte-derived macrophages; and
(b) permitting viral replication in the monocyte-derived macrophages, where the virus is either latent in the monocytes or exogenously added to the culture.

### Claim 39 (depends on 38)

A method of claim 38, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83 and CD14.

### Claim 40 (depends on 38)

A method of claim 38, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 41 (depends on 38)

A method of claim 38, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 42 (depends on 41)

A method of claim 41, wherein the virus is CMV.

### Claim 43 (depends on 38)

A method of claim 38, wherein the monocyte-derived macrophages are human.

### Claim 44

A method for screening for inhibitors of virus production using virally permissive monocyte-derived macrophages, the method comprising the steps of:
(a) culturing CD14+ monocytes under conditions where the monocytes exposed to conditioned media comprising IFNγ in an amount sufficient to activate the monocytes to differentiate into virally permissive monocyte-derived macrophages;
(b) permitting viral replication in the monocyte-derived macrophages, where the virus is either latent in the monocytes or exogenously added to the culture;
(c) contacting the monocyte-derived macrophages of step (b) with substances suspected of having the ability to inhibit viral production; and
(d) detecting the level of virus production in the monocytes-derived macrophages.

### Claim 45 (depends on 44)

A method of claim 44, wherein the monocyte-derived macrophages have a majority population of cell bearing CD83 and CD14.

### Claim 46 (depends on 44)

A method of claim 44, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 47 (depends on 44)

A method of claim 44, wherein the virus is latent.

### Claim 48 (depends on 44)

A method of claim 44, wherein the monocyte-derived macrophages are human.

### Claim 49 (depends on 44)

A method of claim 44, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 50 (depends on 49)

A method of claim 49, wherein the virus is CMV.

### Claim 51

A stable culture of virally permissive monocyte-derived macrophages, wherein the monocyte-derived macrophages are derived from CD14+ monocytes exposed to conditioned media comprising IFNγ in an amount sufficient to and for a time sufficient to: (i) stimulate active differentiation of the CD14+ monocytes into monocyte-derived macrophages, and (ii) stimulate viral production in the monocyte-derived macrophages; and, wherein the virally permissive monocyte-derived macrophages produce at least 10,000 fold greater virus than non-allogeneically stimulated monocytes.

### Claim 52 (depends on 51)

A culture of claim 51, wherein the majority of the monocyte-derived macrophages bear CD83 and CD14.

### Claim 53 (depends on 51)

A culture of claim 51, wherein the majority of the monocyte-derived macrophages bear CD83, CD68, CD1a, CD64, and CD14.

### Claim 54 (depends on 51)

A culture of claim 51, wherein the monocyte-derived macrophages produce a virus selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 55 (depends on 54)

A culture of claim 54, wherein the virus is CMV.

### Claim 56

A stable culture of virally permissive monocyte-derived macrophages having a population defined as at least 85% bearing CD83 and CD14.

### Claim 57 (depends on 56)

A culture of claim 56, wherein the population has at least 85% of the cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 58 (depends on 56)

A culture of claim 56, wherein the virus is latent.

### Claim 59 (depends on 56)

A culture of claim 56, wherein the monocyte-derived macrophages produce a virus selected from the group consisting of cytomegalovirus (CMV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human herpes virus 6 (HHV6), human herpes virus 7 (HHV7), and human herpes virus 8 (HHV8).

### Claim 60 (depends on 59)

A culture of claim 59, wherein the virus is CMV.

### Claim 61 (depends on 56)

A culture of claim 56, wherein the monocyte-derived macrophages are human.

### Claim 62

A method of culturing virally permissive monocyte-derived macrophages, the method comprising the step of culturing CD14+ monocytes under conditions where the monocytes are exposed to conditioned media comprising IFNγ in an amount sufficient to activate the monocytes to differentiate into virally permissive monocyte-derived macrophages.

### Claim 63 (depends on 62)

A method of claim 62, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83 and CD14.

### Claim 64 (depends on 62)

A method of claim 62, wherein the monocyte derived-macrophages have a majority population of cells bearing CD83, CD68, CD1a, CD64, and CD14.

### Claim 65 (depends on 62)

A method of claim 62, wherein the monocyte-derived macrophages are human.
